Loading...
Keywords
Last Name
Institution
 Back to Details

Connection

J. Steven Leeder to Pharmacogenetics

This is a "connection" page, showing publications J. Steven Leeder has written about Pharmacogenetics.

 
Connection Strength
  
 
 
8.701
  
  1. McLaughlin MJ, Wagner J, Shakhnovich V, Carleton B, Leeder JS. Considerations for Implementing Precision Therapeutics for Children. Clin Transl Sci. 2019 03; 12(2):140-150.
    View in: PubMed
    Score: 0.593
  2. Lewis T, Leeder JS. Pharmacogenomics and implementation of precision therapeutics in the neonatal ICU: a new frontier? Pharmacogenomics. 2018 11; 19(16):1231-1233.
    View in: PubMed
    Score: 0.582
  3. McLaughlin MJ, He Y, Brunstrom-Hernandez J, Thio LL, Carleton BC, Ross CJD, Gaedigk A, Lewandowski A, Dai H, Jusko WJ, Leeder JS. Pharmacogenomic Variability of Oral Baclofen Clearance and Clinical Response in Children With Cerebral Palsy. PM R. 2018 03; 10(3):235-243.
    View in: PubMed
    Score: 0.539
  4. Gaedigk A, Sangkuhl K, Whirl-Carrillo M, Klein T, Leeder JS. Prediction of CYP2D6 phenotype from genotype across world populations. Genet Med. 2017 01; 19(1):69-76.
    View in: PubMed
    Score: 0.497
  5. Leeder JS. Meaningful use and clinical utility of preemptive pharmacogenetic testing: (re)view from a CYP2D6 poor metabolizer. Clin Pharmacol Ther. 2015 Feb; 97(2):119-21.
    View in: PubMed
    Score: 0.446
  6. Leeder JS, Gaedigk A. CYP2D6 and pharmacogenomics: where does future research need to focus? Part 2: clinical aspects. Pharmacogenomics. 2014 Jun; 15(8):1055-8.
    View in: PubMed
    Score: 0.430
  7. Leeder JS, Kearns GL. Interpreting pharmacogenetic data in the developing neonate: the challenge of hitting a moving target. Clin Pharmacol Ther. 2012 Oct; 92(4):434-6.
    View in: PubMed
    Score: 0.381
  8. Wagner J, Leeder JS. Pediatric pharmacogenomics: a systematic assessment of ontogeny and genetic variation to guide the design of statin studies in children. Pediatr Clin North Am. 2012 Oct; 59(5):1017-37.
    View in: PubMed
    Score: 0.380
  9. Leeder JS, Lantos J, Spielberg SP. Conference scene: pediatric pharmacogenomics and personalized medicine. Pharmacogenomics. 2010 Dec; 11(12):1691-702.
    View in: PubMed
    Score: 0.337
  10. Becker ML, Leeder JS. Identifying genomic and developmental causes of adverse drug reactions in children. Pharmacogenomics. 2010 Nov; 11(11):1591-602.
    View in: PubMed
    Score: 0.335
  11. Leeder JS. Developmental pharmacogenetics: a general paradigm for application to neonatal pharmacology and toxicology. Clin Pharmacol Ther. 2009 Dec; 86(6):678-82.
    View in: PubMed
    Score: 0.313
  12. Leeder JS, Spielberg SP. Personalized medicine: reality and reality checks. Ann Pharmacother. 2009 May; 43(5):963-6.
    View in: PubMed
    Score: 0.302
  13. Adjei AA, Gaedigk A, Simon SD, Weinshilboum RM, Leeder JS. Interindividual variability in acetaminophen sulfation by human fetal liver: implications for pharmacogenetic investigations of drug-induced birth defects. Birth Defects Res A Clin Mol Teratol. 2008 Mar; 82(3):155-65.
    View in: PubMed
    Score: 0.279
  14. Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, Leeder JS. The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther. 2008 Feb; 83(2):234-42.
    View in: PubMed
    Score: 0.272
  15. Leeder JS, Mitchell AA. Application of pharmacogenomic strategies to the study of drug-induced birth defects. Clin Pharmacol Ther. 2007 Apr; 81(4):595-9.
    View in: PubMed
    Score: 0.260
  16. Leeder JS. Translating pharmacogenetics and pharmacogenomics into drug development for clinical pediatrics and beyond. Drug Discov Today. 2004 Jul 01; 9(13):567-73.
    View in: PubMed
    Score: 0.216
  17. Leeder JS. Developmental and pediatric pharmacogenomics. Pharmacogenomics. 2003 May; 4(3):331-41.
    View in: PubMed
    Score: 0.199
  18. Leeder JS, Kearns GL. The challenges of delivering pharmacogenomics into clinical pediatrics. Pharmacogenomics J. 2002; 2(3):141-3.
    View in: PubMed
    Score: 0.182
  19. Leeder JS. Pharmacogenetics and pharmacogenomics. Pediatr Clin North Am. 2001 Jun; 48(3):765-81.
    View in: PubMed
    Score: 0.175
  20. Hicks JK, Bishop JR, Gammal RS, Sangkuhl K, Bousman CA, Leeder JS, Llerena A, Mueller DJ, Ramsey LB, Scott SA, Skaar TC, Caudle KE, Klein TE, Gaedigk A. A Call for Clear and Consistent Communications Regarding the Role of Pharmacogenetics in Antidepressant Pharmacotherapy. Clin Pharmacol Ther. 2020 01; 107(1):50-52.
    View in: PubMed
    Score: 0.156
  21. Brown JT, Bishop JR, Sangkuhl K, Nurmi EL, Mueller DJ, Dinh JC, Gaedigk A, Klein TE, Caudle KE, McCracken JT, de Leon J, Leeder JS. Clinical Pharmacogenetics Implementation Consortium Guideline for Cytochrome P450 (CYP)2D6 Genotype and Atomoxetine Therapy. Clin Pharmacol Ther. 2019 07; 106(1):94-102.
    View in: PubMed
    Score: 0.151
  22. Volpi S, Bult CJ, Chisholm RL, Deverka PA, Ginsburg GS, Jacob HJ, Kasapi M, McLeod HL, Roden DM, Williams MS, Green ED, Rodriguez LL, Aronson S, Cavallari LH, Denny JC, Dressler LG, Johnson JA, Klein TE, Leeder JS, Piquette-Miller M, Perera M, Rasmussen-Torvik LJ, Rehm HL, Ritchie MD, Skaar TC, Wagle N, Weinshilboum R, Weitzel KW, Wildin R, Wilson J, Manolio TA, Relling MV. Research Directions in the Clinical Implementation of Pharmacogenomics: An Overview of US Programs and Projects. Clin Pharmacol Ther. 2018 05; 103(5):778-786.
    View in: PubMed
    Score: 0.140
  23. Gaedigk A, Ingelman-Sundberg M, Miller NA, Leeder JS, Whirl-Carrillo M, Klein TE. The Pharmacogene Variation (PharmVar) Consortium: Incorporation of the Human Cytochrome P450 (CYP) Allele Nomenclature Database. Clin Pharmacol Ther. 2018 03; 103(3):399-401.
    View in: PubMed
    Score: 0.137
  24. Leeder JS, Kearns GL. Pharmacogenetics in pediatrics. Implications for practice. Pediatr Clin North Am. 1997 Feb; 44(1):55-77.
    View in: PubMed
    Score: 0.129
  25. Lewis T, Dinh J, Leeder JS. Genetic determinants of fetal opiate exposure and risk of neonatal abstinence syndrome: Knowledge deficits and prospects for future research. Clin Pharmacol Ther. 2015 Sep; 98(3):309-20.
    View in: PubMed
    Score: 0.116
  26. Hicks JK, Bishop JR, Sangkuhl K, M?ller DJ, Ji Y, Leckband SG, Leeder JS, Graham RL, Chiulli DL, LLerena A, Skaar TC, Scott SA, Stingl JC, Klein TE, Caudle KE, Gaedigk A. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors. Clin Pharmacol Ther. 2015 Aug; 98(2):127-34.
    View in: PubMed
    Score: 0.116
  27. de Wildt SN, Tibboel D, Leeder JS. Drug metabolism for the paediatrician. Arch Dis Child. 2014 Dec; 99(12):1137-42.
    View in: PubMed
    Score: 0.109
  28. Leeder JS, Brown JT, Soden SE. Individualizing the use of medications in children: making Goldilocks happy. Clin Pharmacol Ther. 2014 Sep; 96(3):304-6.
    View in: PubMed
    Score: 0.108
  29. Gaedigk A, Leeder JS. CYP2D6 and pharmacogenomics: where does future research need to focus? Part 1: technical aspects. Pharmacogenomics. 2014 Mar; 15(4):407-10.
    View in: PubMed
    Score: 0.106
  30. Crews KR, Gaedigk A, Dunnenberger HM, Leeder JS, Klein TE, Caudle KE, Haidar CE, Shen DD, Callaghan JT, Sadhasivam S, Prows CA, Kharasch ED, Skaar TC. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update. Clin Pharmacol Ther. 2014 Apr; 95(4):376-82.
    View in: PubMed
    Score: 0.105
  31. Goldman J, Becker ML, Jones B, Clements M, Leeder JS. Development of biomarkers to optimize pediatric patient management: what makes children different? Biomark Med. 2011 Dec; 5(6):781-94.
    View in: PubMed
    Score: 0.090
  32. Leeder JS, Kearns GL, Spielberg SP, van den Anker J. Understanding the relative roles of pharmacogenetics and ontogeny in pediatric drug development and regulatory science. J Clin Pharmacol. 2010 Dec; 50(12):1377-87.
    View in: PubMed
    Score: 0.080
  33. Koren G, Cairns J, Chitayat D, Gaedigk A, Leeder SJ. Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. Lancet. 2006 Aug 19; 368(9536):704.
    View in: PubMed
    Score: 0.063
  34. Bousman CA, Stevenson JM, Ramsey LB, Sangkuhl K, Hicks JK, Strawn JR, Singh AB, Rua?o G, Mueller DJ, Tsermpini EE, Brown JT, Bell GC, Leeder JS, Gaedigk A, Scott SA, Klein TE, Caudle KE, Bishop JR. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023 07; 114(1):51-68.
    View in: PubMed
    Score: 0.050
  35. Seefelder C, Leeder JS. Cytochrome P450 pharmacogenetics and anaesthesia. Paediatr Anaesth. 2002 Nov; 12(9):810-1.
    View in: PubMed
    Score: 0.048
  36. Hertz DL, Ramsey LB, Gopalakrishnan M, Leeder JS, Van Driest SL. Analysis Approaches to Identify Pharmacogenetic Associations With Pharmacodynamics. Clin Pharmacol Ther. 2021 09; 110(3):589-594.
    View in: PubMed
    Score: 0.044
  37. de Wildt SN, Kearns GL, Leeder JS, van den Anker JN. Glucuronidation in humans. Pharmacogenetic and developmental aspects. Clin Pharmacokinet. 1999 Jun; 36(6):439-52.
    View in: PubMed
    Score: 0.038
  38. Huddart R, Leeder JS, Altman RB, Klein TE. PharmGKB summary: clobazam pathway, pharmacokinetics. Pharmacogenet Genomics. 2018 04; 28(4):110-115.
    View in: PubMed
    Score: 0.035
  39. Pearce RE, Gaedigk R, Twist GP, Dai H, Riffel AK, Leeder JS, Gaedigk A. Developmental Expression of CYP2B6: A Comprehensive Analysis of mRNA Expression, Protein Content and Bupropion Hydroxylase Activity and the Impact of Genetic Variation. Drug Metab Dispos. 2016 07; 44(7):948-58.
    View in: PubMed
    Score: 0.030
  40. Ghodke-Puranik Y, Thorn CF, Lamba JK, Leeder JS, Song W, Birnbaum AK, Altman RB, Klein TE. Valproic acid pathway: pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics. 2013 Apr; 23(4):236-41.
    View in: PubMed
    Score: 0.025
  41. Stockmann C, Fassl B, Gaedigk R, Nkoy F, Uchida DA, Monson S, Reilly CA, Leeder JS, Yost GS, Ward RM. Fluticasone propionate pharmacogenetics: CYP3A4*22 polymorphism and pediatric asthma control. J Pediatr. 2013 Jun; 162(6):1222-7, 1227.e1-2.
    View in: PubMed
    Score: 0.024
  42. Thorn CF, Whirl-Carrillo M, Leeder JS, Klein TE, Altman RB. PharmGKB summary: phenytoin pathway. Pharmacogenet Genomics. 2012 Jun; 22(6):466-70.
    View in: PubMed
    Score: 0.023
  43. Thorn CF, Leckband SG, Kelsoe J, Leeder JS, M?ller DJ, Klein TE, Altman RB. PharmGKB summary: carbamazepine pathway. Pharmacogenet Genomics. 2011 Dec; 21(12):906-10.
    View in: PubMed
    Score: 0.023
  44. Carleton B, Poole R, Smith M, Leeder J, Ghannadan R, Ross C, Phillips M, Hayden M. Adverse drug reaction active surveillance: developing a national network in Canada's children's hospitals. Pharmacoepidemiol Drug Saf. 2009 Aug; 18(8):713-21.
    View in: PubMed
    Score: 0.019
  45. Madadi P, Ross CJ, Hayden MR, Carleton BC, Gaedigk A, Leeder JS, Koren G. Pharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breastfeeding: a case-control study. Clin Pharmacol Ther. 2009 Jan; 85(1):31-5.
    View in: PubMed
    Score: 0.018
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.